Clinical Trial Results:
A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis
Summary
|
|
EudraCT number |
2006-002982-38 |
Trial protocol |
BE CZ AT LT SK DE FI FR EE DK IT GR PT ES |
Global completion date |
16 Sep 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Jun 2016
|
First version publication date |
24 Jun 2016
|
Other versions |
|
Summary report(s) |
2006-002982-38_CT.gov results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.